• Precirix dosed first patients in Phase I/II clinical study evaluating CAM-H2 in HER2-positive metastatic cancer

    Wednesday October 6th 2021

  • Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease

    Monday October 4th 2021

  • Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)

    Monday October 4th 2021

  • ExeVir announces first patient enrolled in phase 1b/2 clinical study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

    Wednesday September 1st 2021

  • Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science

    Tuesday August 17th 2021

  • Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

    Thursday July 15th 2021

  • Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

    Thursday July 15th 2021

  • Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis

    Monday July 12th 2021

  • Your news here?

  • imec’s ultrasound sensor technology yields accurate pulse wave velocity and blood pressure values

    Tuesday June 29th 2021

  • OXURION completes patient enrollment for Part A of Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

    Tuesday June 8th 2021

  • Sequana Medical announces first patient enrolled in SAHARA DESERT

    Tuesday June 1st 2021


Strategic Partners